Lonapegsomatropin + Somatropin
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Trial Timeline
Dec 3, 2020 → Dec 1, 2023
NCT ID
NCT04615273About Lonapegsomatropin + Somatropin
Lonapegsomatropin + Somatropin is a phase 3 stage product being developed by Ascendis Pharma for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT04615273. Target conditions include Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05690386 | Phase 2 | Active |
| NCT04615273 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency